Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 705

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Open access
VanBlargan, Laura A., Errico, John M., Halfmann, Peter J., Zost, Seth J., Crowe, James E., Purcell, Lisa A., Kawaoka, Yoshihiro, Corti, Davide, Fremont, Daved H., Diamond, Michael S.·2022·Nature Medicine
DOI 10.1038/s41591-021-01678-y

Published version of a preprint

Open this paper in CoChat — free account

Abstract

The emergence of the highly transmissible B.1.1.529 Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. In this study, we tested a panel of anti-receptor-binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 (sotrovimab)), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Eli Lilly (LY-CoV555 and LY-CoV016) and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987 and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, ~12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use might lose efficacy against the B.1.1.529 Omicron variant. New in vitro data suggest that the new SARS-CoV-2 Omicron variant is likely to escape neutralization by most therapeutic antibodies currently available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01678-y

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 30

  1. Sempowski, G. D., Saunders, K. O., Acharya, P., Wiehe, K. J. & Haynes, B. F. Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19. Cell 181, 1458–1463 (2020). · DOI
  2. Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021). · DOI · Paper page
  3. Chen, R. E. et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature 596, 103–108 (2021). · DOI · Paper page
  4. Callaway, E. & Ledford, H. How bad is Omicron? What scientists know so far. Nature 600, 197–199 (2021). · DOI · Paper page
  5. Torjesen, I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ 375, n2943 (2021). · DOI · Paper page
  6. Chen, J., Wang, R., Gilby, N. B. & Wei, G. W. Omicron (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. Preprint at https://arxiv.org/abs/2112.01318 (2021). · DOI · Paper page
  7. Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020). · DOI · Paper page
  8. Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 325, 632–644 (2021). · DOI · Paper page
  9. Kim, C. et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat. Commun. 12, 288 (2021). · DOI · Paper page
  10. VanBlargan, L. A. et al. A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. Immunity 54, 2399–2416 (2021). · DOI
  11. Case, J. B. et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe 28, 475–485 (2020). · DOI · Paper page
  12. Cathcart, A. L. et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. Preprint at https://www.biorxiv.org/content/10.1101/2021.03.09.434607v8 (2021). · DOI · Paper page
  13. Suryadevara, N. et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 184, 2316–2331 (2021). · DOI · Paper page
  14. Golcuk, M., Yildiz, A. & Gur, M. The Omicron variant increases the interactions of SARS-CoV-2 spike glycoprotein with ACE2. Preprint at https://www.biorxiv.org/content/10.1101/2021.12.06.471377v1 (2021). · doi:10.1101/2021.12.06.471377
  15. Lempp, F. A. et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature 598, 342–347 (2021). · DOI · Paper page
  16. Ford, C. T., Machado, D. J. & Janies, D. A. Predictions of the SARS-CoV-2 Omicron variant (B.1.1.529) spike protein receptor-binding domain structure and neutralizing antibody interactions. Preprint at https://www.biorxiv.org/content/10.1101/2021.12.03.471024v3.full (2021). · DOI · Paper page
  17. Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature https://doi.org/10.1038/d41586-021-03825-4 (2021). · doi:10.1038/d41586-021-03825-4 · Paper page
  18. Callaway, E. Omicron likely to weaken COVID vaccine protection. Nature 600, 367–368 (2021). · DOI
  19. Cele, S. et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.08.21267417v1 (2021). · DOI · Paper page
  20. Dejnirattisai, W. et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.10.21267534v1 (2021). · DOI
  21. Kim, J. H., Marks, F. & Clemens, J. D. Looking beyond COVID-19 vaccine phase 3 trials. Nat. Med. 27, 205–211 (2021). · DOI · Paper page
  22. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021). · DOI · Paper page
  23. Schäfer, A. et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J. Exp. Med. 218, e20201993 (2021). · DOI · Paper page
  24. Bailey, A. L. & Diamond, M. S. A Crisp(r) new perspective on SARS-CoV-2 biology. Cell 184, 15–17 (2021). · DOI
  25. Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587–16595 (2020). · DOI · Paper page
  26. Zost, S. J. et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat. Med. 26, 1422–1427 (2020). · DOI · Paper page
  27. Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Trans. Med. 13, eabf1906 (2021). · DOI · Paper page
  28. Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020). · DOI · Paper page
  29. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 (2007). · DOI · Paper page
  30. Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018). · DOI · Paper page

Cited by

See all 705

Metadata

Authors
VanBlargan, L. A., Errico, J. M., Halfmann, P. J., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. S.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2022-01-19
Volume
28
Issue
3
Pages
490-495
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
DOI
10.1038/s41591-021-01678-y
OpenAlex
W4226087845
Cited by
705
References
22
FWCI
77.23
Type
journal article
Language
en
Open access
bronze
Licence
Funders
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI157155, 75N93021C00014, 75N93019C00051, HHSN272201700060C)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. https://app.cochat.ai/papers/10.1038/s41591-021-01678-y
The paper
VanBlargan, L. A., Errico, J. M., Halfmann, P. J., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. S. (2022). An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nature Medicine. https://doi.org/10.1038/s41591-021-01678-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.